Literature DB >> 30773644

N,N-dimethylacrylamide-A new sensitizer in the FreeStyle Libre glucose sensor.

Martin Mowitz1, Anne Herman2, Marie Baeck2, Marléne Isaksson1, Annarita Antelmi1, Nils Hamnerius1, Ann Pontén1, Magnus Bruze1.   

Abstract

BACKGROUND: Isobornyl acrylate (IBOA) has recently been identified as one sensitizer in the FreeStyle Libre glucose sensor. Analyses with gas chromatography-mass spectrometry (GC-MS) have indicated the presence of N,N-dimethylacrylamide (DMAA) in the sensor.
MATERIAL AND METHODS: Seven patients were referred for patch testing after developing skin reactions when using FreeStyle Libre. All patients were patch tested with IBOA and DMAA. Two patients were tested with adhesive patches that had been removed from the sensors "as is," and two patients were tested with acetone extracts of materials from the sensor. The extracts were analysed with GC-MS.
RESULTS: Six patients reacted to both IBOA and DMAA, and one patient reacted only to DMAA. Positive reactions were also observed in both patients tested with the adhesive patch "as is". One patient reacted to both an extract of the adhesive patch and an extract of the sensor itself. When analysed with GC-MS, IBOA was found in both extracts and DMAA was found in the extract of the sensor.
CONCLUSION: Both IBOA and DMAA may be present in adhesives used in medical devices such as glucose sensors or insulin pumps, and should be patch tested when suspected contact allergic reactions to these products are investigated.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990N,N-dimethylacrylamide; FreeStyle Libre; adhesive; allergic contact dermatitis; diabetes mellitus; gas chromatography-mass spectrometry; glucose sensor; isobornyl acrylate; medical device

Mesh:

Substances:

Year:  2019        PMID: 30773644     DOI: 10.1111/cod.13243

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  7 in total

1.  Five-Month Follow-up Shows No Improvement in Dermatological Complications in Children With Type 1 Diabetes Using Continuous Glucose Monitoring Systems and Insulin Pumps.

Authors:  Anna T Weng; Claus Zachariae; Karl B Christensen; Jannet Svensson; Anna K Berg
Journal:  J Diabetes Sci Technol       Date:  2019-10-16

2.  Cutaneous Reactions to Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion Devices in Type 1 Diabetes Mellitus.

Authors:  Rachel S Rigo; Laura E Levin; Donald V Belsito; Maria C Garzon; Rachelle Gandica; Kristen M Williams
Journal:  J Diabetes Sci Technol       Date:  2020-05-09

3.  Cutaneous Complications With Continuous or Flash Glucose Monitoring Use: Systematic Review of Trials and Observational Studies.

Authors:  Nurul A Mohd Asarani; Andrew N Reynolds; Sara E Boucher; Martin de Bock; Benjamin J Wheeler
Journal:  J Diabetes Sci Technol       Date:  2019-08-27

4.  High Frequency of Dermatological Complications in Children and Adolescents with Type 1 Diabetes: A Web-Based Survey.

Authors:  Fortunato Lombardo; Stefano Passanisi; Davide Tinti; Maria Francesca Messina; Giuseppina Salzano; Ivana Rabbone
Journal:  J Diabetes Sci Technol       Date:  2020-08-06

5.  Allergic Contact Dermatitis in a Patient After Five Years of Use of Omnipod Insulin Pump.

Authors:  Nadia Raison-Peyron; Martin Mowitz; Olivier Dereure; Cecilia Svedman
Journal:  J Diabetes Sci Technol       Date:  2022-07-14

Review 6.  Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices.

Authors:  A Herman; W Uter; T Rustemeyer; M Matura; K Aalto-Korte; J Duus Johansen; M Gonçalo; I R White; A Balato; A M Giménez Arnau; K Brockow; C G Mortz; V Mahler; A Goossens
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-06       Impact factor: 6.166

Review 7.  Contact Allergy-Emerging Allergens and Public Health Impact.

Authors:  Wolfgang Uter; Thomas Werfel; Jean-Pierre Lepoittevin; Ian R White
Journal:  Int J Environ Res Public Health       Date:  2020-04-01       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.